Healthy dogs were administered acute oral doses of D-allulose (also called D-psicose) to evaluate its
toxicity. Six dogs received oral doses of either a placebo or D-allulose solution (1 and 4 g/kg) on three
different study days. One dog experienced vomiting, and five dogs showed transient diarrhea when 4 g/kg of
D-allulose was administered. All dogs were active and had a good appetite throughout the study period. Blood
glucose concentration slightly decreased without a rise in plasma insulin concentration 2 hr after D-allulose
administration. Plasma alkaline phosphatase activities showed a mild increase between 12 and 48 hr after
D-allulose administration. These data suggested that a single oral dose of D-allulose does not show severe
toxicity in dogs.
D-allulose is a C-3 epimer of D-fructose and has recently been investigated for its
hypoglycemic effects. In the present study, the effects of D-allulose on glucose
metabolism were evaluated in healthy dogs administrated sugar or food. The oral
administrations of D-allulose decreased plasma glucose concentrations after oral glucose
or maltose administration, with a diminished plasma insulin rise. The glucose suppressive
effect of D-allulose was also observed after intravenous glucose administrations without
increase in plasma insulin concentration. In contrast, D-allulose showed no effect on
plasma glucose and insulin concentrations after feeding. The present results suggest that
D-allulose administration may be beneficial in dogs with impaired glucose tolerance.
Further studies investigating the therapeutic efficacy of D-allulose in diabetic dogs are
required.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.